Marina M López-Olañeta1, María Villalba1, Jesús M Gómez-Salinero1, Luis J Jiménez-Borreguero2, Ross Breckenridge3, Paula Ortiz-Sánchez1, Pablo García-Pavía4, Borja Ibáñez5, Enrique Lara-Pezzi6. 1. Cardiovascular Development and Repair Department, Centro Nacional de Investigaciones Cardiovasculares, Melchor Fernández Almagro 3, Madrid 28029, Spain. 2. Epidemiology, Atherothrombosis and Imaging Department, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain Hospital Universitario de la Princesa, Madrid, Spain. 3. National Institute for Medical Research, Medical Research Council, London, UK. 4. Servicio de Cardiología, Hospital Puerta de Hierro de Majadahonda, Madrid, Spain. 5. Epidemiology, Atherothrombosis and Imaging Department, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain Cardiovascular Institute, Hospital Clinico San Carlos, Madrid, Spain. 6. Cardiovascular Development and Repair Department, Centro Nacional de Investigaciones Cardiovasculares, Melchor Fernández Almagro 3, Madrid 28029, Spain National Heart and Lung Institute, Imperial College London, London, UK elara@cnic.es.
Abstract
AIMS: Ventricular remodelling following myocardial infarction progressively leads to loss of contractile capacity and heart failure. Although calcineurin promotes maladaptive cardiac hypertrophy, we recently showed that the calcineurin splicing variant, CnAβ1, has beneficial effects on the infarcted heart. However, whether this variant limits necrosis or improves remodelling is still unknown, precluding translation to the clinical arena. Here, we explored the effects and therapeutic potential of CnAβ1 overexpression post-infarction. METHODS AND RESULTS: Double transgenic mice with inducible cardiomyocyte-specific overexpression of CnAβ1 underwent left coronary artery ligation followed by reperfusion. Echocardiographic analysis showed depressed cardiac function in all infarcted mice 3 days post-infarction. Induction of CnAβ1 overexpression 1 week after infarction improved function and reduced ventricular dilatation. CnAβ1-overexpressing mice showed shorter, thicker scars, and reduced infarct expansion, accompanied by reduced myocardial remodelling. CnAβ1 induced vascular endothelial growth factor (VEGF) expression in cardiomyocytes, which resulted in increased infarct vascularization. This paracrine angiogenic effect of CnAβ1 was mediated by activation of the Akt/mammalian target of rapamycin pathway and VEGF. CONCLUSIONS: Our results indicate that CnAβ1 exerts beneficial effects on the infarcted heart by promoting infarct vascularization and preventing infarct expansion. These findings emphasize the translational potential of CnAβ1 for gene-based therapies. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Ventricular remodelling following myocardial infarction progressively leads to loss of contractile capacity and heart failure. Although calcineurin promotes maladaptive cardiac hypertrophy, we recently showed that the calcineurin splicing variant, CnAβ1, has beneficial effects on the infarcted heart. However, whether this variant limits necrosis or improves remodelling is still unknown, precluding translation to the clinical arena. Here, we explored the effects and therapeutic potential of CnAβ1 overexpression post-infarction. METHODS AND RESULTS: Double transgenic mice with inducible cardiomyocyte-specific overexpression of CnAβ1 underwent left coronary artery ligation followed by reperfusion. Echocardiographic analysis showed depressed cardiac function in all infarctedmice 3 days post-infarction. Induction of CnAβ1 overexpression 1 week after infarction improved function and reduced ventricular dilatation. CnAβ1-overexpressing mice showed shorter, thicker scars, and reduced infarct expansion, accompanied by reduced myocardial remodelling. CnAβ1 induced vascular endothelial growth factor (VEGF) expression in cardiomyocytes, which resulted in increased infarct vascularization. This paracrine angiogenic effect of CnAβ1 was mediated by activation of the Akt/mammalian target of rapamycin pathway and VEGF. CONCLUSIONS: Our results indicate that CnAβ1 exerts beneficial effects on the infarcted heart by promoting infarct vascularization and preventing infarct expansion. These findings emphasize the translational potential of CnAβ1 for gene-based therapies. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Emanuele Barbato; Paul J Barton; Jozef Bartunek; Sally Huber; Borja Ibanez; Daniel P Judge; Enrique Lara-Pezzi; Craig M Stolen; Angela Taylor; Jennifer L Hall Journal: J Cardiovasc Transl Res Date: 2015-10-09 Impact factor: 4.132
Authors: Enrique Lara-Pezzi; Philippe Menasché; Jean-Hugues Trouvin; Lina Badimón; John P A Ioannidis; Joseph C Wu; Joseph A Hill; Walter J Koch; Albert F De Felice; Peter de Waele; Valérie Steenwinckel; Roger J Hajjar; Andreas M Zeiher Journal: J Cardiovasc Transl Res Date: 2015-01-21 Impact factor: 4.132
Authors: Diego Herrero; Susana Cañón; Beatriz Pelacho; María Salvador-Bernáldez; Susana Aguilar; Cristina Pogontke; Rosa María Carmona; Jesús María Salvador; Jose María Perez-Pomares; Ophir David Klein; Felipe Prósper; Luis Jesús Jimenez-Borreguero; Antonio Bernad Journal: Arterioscler Thromb Vasc Biol Date: 2018-09 Impact factor: 8.311
Authors: Zoltán V Varga; Márton Pipicz; Júlia A Baán; Tamás Baranyai; Gábor Koncsos; Przemyslaw Leszek; Mariusz Kuśmierczyk; Fátima Sánchez-Cabo; Pablo García-Pavía; Gábor J Brenner; Zoltán Giricz; Tamás Csont; Luca Mendler; Enrique Lara-Pezzi; Pál Pacher; Péter Ferdinandy Journal: Front Physiol Date: 2017-11-22 Impact factor: 4.566
Authors: Enrique Gallego-Colon; Maria Villalba; Joanne Tonkin; Francisco Cruz; Juan Antonio Bernal; Luis J Jimenez-Borregureo; Michael D Schneider; Enrique Lara-Pezzi; Nadia Rosenthal Journal: NPJ Regen Med Date: 2016-06-09